Multiple sclerosis (MS) affects an estimated 400,000 people in the U.S., with approximately 10,000 new cases reported every year. As a chronic and progressive neurologic disease that requires lifelong, dynamic treatment via costly, high-touch medications that also require special handling and storage, multiple sclerosis therapies are often delivered via specialty pharmacy programs.
The NASP/CSPE MS Core Curriculum Series is intended to increase specialty clinicians’ knowledge of the evolving MS treatment paradigm and provide the necessary professional education to counsel patients and caregivers on the myriad therapeutic options, routes of administration, and behavioral/clinical/financial variables that must be considered alongside drug therapy choices when treating MS across care settings. As the third installment in the four-module NASP/CSPE MS Core Curriculum Series, this activity discusses the transitions of care, patient adherence strategies and financial considerations in the management of MS.
The target audience for this activity includes pharmacists and nurses caring for MS patients. Upon completion of this activity, participants will be able to:
- Describe methods for minimizing the impact of cost on the management of Multiple Sclerosis (MS)
- Describe specific strategies that a Specialty Pharmacist may utilize to optimize treatment in MS
- Identify the factors affecting adherence in individuals with MS
- Discuss strategies to optimize long-term patient adherence
- Outline a comprehensive patient care journey for a typical MS patient receiving specialty pharmacy services
Susan L. Allen, PharmD, R.P., CSP
Senior Director, Clinical Operations
Amber Pharmacy & Hy-Vee Pharmacy Solutions
Co-Chair, NASP Education Committee
Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP
Senior Director, Specialty Clinical Services
Managed Health Care Associates, Inc.
Co-Chair, NASP Education Committee
Florham Park, New Jersey
Stacia Olsen, BSN, RN
Clinical Nurse Coordinator
Susan Allen, PharmD; Aimee Banks, PharmD; Joy Derwenskus, DO, MS; Stephanie LaPointe, PharmD; Brandon Markley, PharmD; Mel Nelson, PharmD; Stacey Ness, PharmD; Libin Philip, PharmD.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Susan Allen, Stacey Ness, and Stacia Olsen have no relevant commercial and/or financial relationships to disclose. Joy Derwenskus has served as a Speaker and/or Consultant for EMD Serono, Genzyme, a Sanofi Company, Novartis, and Teva Pharmaceuticals USA. Aimee Banks, Brandon Markley, Stephanie LaPointe, Melissa Nelson, and Libin Philip have no relevant commercial and/or financial relationships to disclose.
Release Date: 10-18-2019
Expiration Date: 10-18-2022
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-516-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is supported by educational grants from Bayer, Genzyme, a Sanofi Company, and Novartis.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.